Ultromics vs Us2.ai
Updated October 16, 2026
Echo lab and cardiology leaders adding AI to echocardiograms often compare Ultromics and Us2.ai. Ultromics flags patients likely to have hard-to-spot heart failure or cardiac amyloidosis from a standard echo, while Us2.ai takes measurements across the whole study and drafts the report to speed reading. One finds hidden disease and the other clears the backlog.
Our analysts compared Ultromics and Us2.ai on clinical focus, reading speed, cleared uses, reimbursement, and deployment, using the HIR review of each company and each vendor's news pages. In the following sections, we compare them in one table, describe the lab each fits, and list each company's news this year.
Ultromics vs Us2.ai at a glance, October 2026
| What buyers weigh | Ultromics | Us2.ai |
|---|---|---|
| Pricing model | Custom contract quoted by Ultromics. | Custom contract quoted by Us2.ai, sold directly and through imaging partners such as Fujifilm. |
| What drives cost | Echo volume, which EchoGo products are used, the number of sites, and integration with the echo reporting system. | Study volume, the number of sites and ultrasound machines, how the software connects to the PACS and reporting system, and whether amyloidosis detection is included. |
| Main job | Flags likely HFpEF and cardiac amyloidosis on routine echoes; no new hardware. | Full echo measurements and a draft report in under two minutes from any ultrasound machine. |
| Clinical focus | Heart failure and amyloidosis programs that want missed cases found on routine scans. | Labs with long reading backlogs that want guideline-based measurements done the same way on every study. |
| Outcomes scored | Scores 7.5 on missed heart failure found. | Scores 7.8 on faster, more consistent echo reports. Higher score |
| Product depth | Scores 7.9 for its echo AI product. | Scores 8.2 for its echo AI product. Higher score |
| Fitting into the echo lab | Scores 7.1; contract and integration in 1-3 months, first lab live in 2-4 months. | Scores 7.5; contract and PACS connection in 1-3 months, first lab live in 1-2 months. Higher score |
| Reimbursement angle | Medicare pays for its use; strong for health systems that want an AI tool Medicare pays for. Clear edge | Sold directly and through imaging partners such as Fujifilm; reimbursement is not the headline story. |
| Where both are weak | Groups that want AI across X-ray, CT, and MRI; practices with low echo volumes. | Sites that read only a handful of echoes a week; buyers who want CT, MRI, or X-ray AI in the same purchase. |
| Time to full value | About 7 to 16 months | About 8 to 17 months |
| What you need first | Echo lab director as clinical lead. | Echo lab medical director. |
| Deal-breaker | Low echo volume. | Few echoes a week. |
| Pricing clarity score | 6.6 | 6.6 |
| HIR overall score | 7.4, Recommend. | 7.7, Recommend. Higher score |
| Best for | Hospital echo labs and cardiology groups that see many patients with shortness of breath. | Hospital echo labs with long reading backlogs and many sonographers. |
| Not a fit for | Groups that want AI across X-ray, CT, and MRI. | Sites that read only a handful of echoes a week. |
Which fits which buyer
Weigh missed diagnoses against reading delays at your lab.
Choose Ultromics if
- You see many patients with unexplained shortness of breath.
- Earlier heart failure diagnosis is a quality goal.
- Medicare payment for the AI read matters to you.
Choose Us2.ai if
- Your echo reading backlog is long.
- You want full measurements and a draft report automatically.
- You have many sonographers and high volume.
Verdict
Us2.ai scores higher and fits busy labs that need speed. Ultromics fits cardiology groups chasing earlier diagnosis of heart failure and amyloidosis.
Some labs use both, one for measurements and one for detection.
Where the two tools are headed in 2027 and beyond
Ultromics: Ultromics shared an American Heart Association lab report on July 22, 2026 finding its heart failure AI may spot the disease earlier than standard care.
Us2.ai: Us2.ai partnered with Corbotics on August 30, 2026 to pair robotic echo scanning with its AI analysis.
Ask each to run on a set of your archived studies.
Methodology
Each row comes from the HIR reviews of Ultromics and Us2.ai, scored under the HIR method, and from each vendor's public pricing where it exists. Any published price for Ultromics or Us2.ai was checked on that vendor's own site on October 16, 2026.
A green check marks a clear edge for Ultromics or Us2.ai only where their review scores differ by at least 0.3 points or the two reviews show a plain difference. Rows with nothing published for either Ultromics or Us2.ai are left out, and time to full value for each adds up the rollout stages in its review.
Sources
- HIR review of Ultromics and HIR review of Us2.ai
- Ultromics website
- Us2.ai website
- Ultromics AHA lab report, July 22, 2026
- Us2.ai and Corbotics, August 30, 2026